Overview: Rubella Antibodies Panel
Introduction: The Rubella Antibodies Panel is a diagnostic tool designed to screen for rubella immunity using serum samples. In India, rubella causes congenital rubella syndrome (CRS) in ~20-30 percent of fetuses if maternal infection occurs in first trimester, with CRS prevalence ~1-5 per 10,000 births in unscreened populations. High morbidity from under-testing in rural/low-SES pregnant women or MMR vaccine candidates, limited serology labs, delayed vaccination or counseling leading to preventable birth defects (deafness, cataracts). Per microbiology practices aligned with ICMR and National Measles-Rubella Elimination Programme guidelines, the test employs immunoassay for rubella IgG and IgM over 1-2 days with high accuracy, valuable for immunity verification or acute infection diagnosis. This diagnostic falls under immunity screening and targets pregnant women, vaccine candidates, or rash cases, addressing accurate detection to guide MMR or post-exposure prophylaxis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise rubella immunity assessment and reducing CRS burden. Its serum-based approach ensures reliable antibody detection.
Other Names: Rubella Ab Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Rubella IgG/IgM standard; in India, integrated in MR elimination.
Purpose: The test assesses 2 parameters including rubella IgG to guide immunity screening, detect acute/past infection, inform vaccination.
Test Parameters: 1. Rubella IgG, 2. Rubella IgM.
Pretest Condition: No fasting required; patients should have pregnancy or vaccine history.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on vaccination, pregnancy, rash.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected non-immunity including CRS, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive IgG indicates immunity; IgM positive acute infection, necessitating specialist input.
Specialist Consultation: Obstetricians or infectious disease specialists should be consulted for management.
Additional Supporting Tests: PCR for confirmation.
Test Limitations: IgM may persist; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, Vaccine Studies India 2023.
